Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Glenmark's first true generic fluticasone propionate (fluticasone propionate) inhaler for asthma maintenance treatment
Small molecule, respiratory disease, inhaled corticosteroid, asthma, generic drug, fluticasone propionate - Read more

FDA approves Johnson & Johnson's Tecvayli (teclistamab) plus Darzalex Faspro combo for relapsed refractory multiple myeloma
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA target, combination therapy - Read more

BioDuro, Cenra API Solutions form Taiwan joint venture for end-to-end API manufacturing services
Joint venture, manufacturing, API production, small molecule - Read more

Daiichi Sankyo, GAIA partner on digital therapeutic app lipodia for hypercholesterolaemia management
Partnership, cardiovascular, digital therapeutics, commercialization - Read more

Alnylam, Tenaya Therapeutics partner on genetic heart disease targets, $10M upfront, $1.13B milestones
Research collaboration, cardiovascular, gene therapy, milestone payments, target identification - Read more

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

Zealand Pharma's petrelintide shows placebo-like tolerability with 10.7% weight loss in Ph2 obesity trial
Protein therapy, metabolic, amylin analog, obesity, weight loss, GLP-1 alternative - Read more

Portal Innovations to open 30,000-square-foot biotech incubator in Salt Lake City by 2027
Biotechnology incubator, strategic, investment, operational - Read more

Forma Life Sciences launches as CDMO focusing on oral solid dose drugs after acquiring BioDuro California operations
Small molecule, strategic, operational, manufacturing - Read more

Galderma doubles Nemluvio peak sales projection to $4B-plus after strong atopic dermatitis launch year
Monoclonal antibody, dermatological, financial, revenue impact - Read more

Science raises $230M Series C, BCI retinal implant for macular degeneration
Brain-computer interface, retinal implant, medical device, age-related macular degeneration - Read more

Atavistik Bio raises $160M Series B, blood disorder treatments development
Rare disease, small molecule, allosteric targeting, blood disorders - Read more

Eli Lilly launches employer connect program for direct Zepbound access, bypassing traditional insurance coverage barriers
GLP-1 agonist, obesity, strategic, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck KGaA's Mavenclad loses US exclusivity to generics, ending €1.2B blockbuster drug's growth era
tRNA therapy, operational, strategic, cost reduction - Read more

Alltrna cuts 35% of workforce in third layoff round before entering clinic with tRNA candidate
tRNA therapy, operational, strategic, cost reduction - Read more

FDA's Høeg reportedly seeks to hire friend Adam Urato, fellow antidepressant pregnancy skeptic
Small molecule, neurological, regulatory, operational - Read more

Merck KGaA drops pipeline assets SW-682 and M9466 from SpringWorks acquisition and Hengrui licensing deal
Small molecule, oncology, strategic, cost reduction - Read more

Bayer discontinues ACTUS-101 Pompe gene therapy from $2B AskBio acquisition to focus on AB-1009 alternative
Gene therapy, rare disease, strategic, operational - Read more

uniQure and FDA clash over sham surgery trial design for Huntington's gene therapy AMT-130
Gene therapy, neurological, regulatory, strategic - Read more

Senior FDA official accuses uniQure of pushing "distorted" data for failed Huntington's gene therapy AMT-130
Gene therapy, neurological, regulatory, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here